Testing SHR-A2102 with other cancer treatments for advanced solid tumors
Official title: A Phase II, Multicenter, Open-Label Study of Safety, Tolerability and Efficacy of SHR-A2102 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors
Run by Shanghai Hengrui Pharmaceutical Co., Ltd. · NCT06895928 · Data updated 2026-11-12
This study is testing a new cancer treatment called SHR-A2102 combined with other therapies to see if it helps people with advanced solid tumors feel better and improve their outcomes.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 400 (estimated) |
| Sponsor | Shanghai Hengrui Pharmaceutical Co., Ltd. Industry-sponsored |
| Locations | 1 site (Taiyuan, Shanxi) |
| Status | Recruiting |
| Started | March 28, 2025 |
| Main results expected | December 2028 |
| Study ends | December 2028 |
| Registry record updated | April 22, 2025 |
| Trial ID | NCT06895928 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 to 70 with measurable advanced solid tumors and good organ function.
✕Probably not a fit
Patients with uncontrolled central nervous system metastases or severe cardiovascular diseases may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial evaluates the safety, tolerability, and efficacy of SHR-A2102 in combination with other antitumor therapies for patients with advanced solid tumors. The study aims to determine the appropriate dosage and assess the overall effectiveness of SHR-A2102 alongside treatments like Bevacizumab and Osimertinib. Participants will be monitored for their response to the treatment and any potential side effects. The trial is designed for patients who meet specific eligibility criteria, ensuring a focused approach to treatment.
Why it matters
Potential benefit: If successful, this study could provide a new effective treatment option for patients with advanced solid tumors.
How similar studies have gone: Other studies have shown promise in using combination therapies for advanced solid tumors, suggesting potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. The age of signing the informed consent is 18 -70 years, regardless of gender. 2. At least one measurable lesion according to RECIST v1.1 criteria. 3. The ECOG score is 0 or 1. 4. Expected survival ≥12 weeks. 5. Good level of organ function. 6. Have the ability to give informed consent and to comply with the treatment plan. 7. Male subjects whose partners are women of childbearing age and female subjects who are fertile are required to use highly effective contraceptive methods. Exclusion Criteria: 1. Inadequately treated central nervous system metastases or the presence of uncontrolled or symptomatic active central nervous system metastases. 2. Spinal cord compression not cured by surgery and/or radiotherapy. 3. Subjects with uncontrolled tumor-related pain. 4. Received antitumor therapy within 4 weeks before the start of the study. 5. Subjects with severe cardiovascular and cerebrovascular disease. 6. History of immunodeficiency, including a positive HIV test.
Where it's running
-
Shanxi Cancer hospital
Taiyuan, Shanxi, China Recruiting
Study contacts
- Study coordinator: Yang Wu
- Email: yang.wu.yw96@hengrui.com
- Phone: +86-0518-82342973
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
AK157D1 injection for advanced solid tumors
A first-in-human Phase 1 study tests AK157D1 injection in adults with unresectable advanced solid tumors to see if it is safe and tolerable and to get early signs of how it behaves in the body and against tumors.
-
ABBV-253 in adults with advanced solid tumors
This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.
-
MK-2010 alone or with other treatments for advanced solid tumors
This trial tests MK-2010, by itself or with other cancer medicines, to see if it helps people with advanced solid tumors.
-
Whole-Body Infrared Heating for Advanced Solid Tumors
This study looks at how ET-SPACE whole-body infrared hyperthermia affects people with advanced solid tumors to see if it changes biology, symptoms, and safety.
-
MK-2010 with Sac-TMT in advanced solid tumors
This study tests MK-2010 combined with sacituzumab tirumotecan (sac-TMT) to see if it can help people with advanced solid tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.